Cargando…
Prostate Cancers Detected During 5α-Reductase Inhibitor Use Are Smaller, De-Differentiated, But Confined when Compared To Controls
Rationale: To compare cancers detected during use of 5α-reductase inhibitors (5αRI) with cancers detected in untreated controls stratified for tumor size. Methods: Prostate biopsies were performed on 235 consecutive patients “for cause” (elevated or rising PSA, positive digital rectal examination, o...
Autores principales: | Lee, Fred, Badalament, Robert A., Hu, Chen, Bousho, Ingrid, Tsodikov, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3297839/ https://www.ncbi.nlm.nih.gov/pubmed/22408685 http://dx.doi.org/10.7150/jca.4123 |
Ejemplares similares
-
Current Status of 5α-Reductase Inhibitors in Prostate Disease Management
por: Kang, Dong Il, et al.
Publicado: (2013) -
Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023) -
Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
por: Busato, Wilson F. S.
Publicado: (2020) -
Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer
por: Bhattacharjee, Biplab, et al.
Publicado: (2011) -
5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)